Center for Drug Evaluation and Research

Center for Drug Evaluation and Research
en:User:Sponge · CC BY-SA 3.0 · source
Name	Center for Drug Evaluation and Research
Formation	1960s
Founder	Food and Drug Administration
Type	United States Department of Health and Human Services center
Headquarters	Silver Spring, Maryland
Leader title	Director
Parent organization	Food and Drug Administration

Center for Drug Evaluation and Research

The Center for Drug Evaluation and Research is a component of the Food and Drug Administration within the United States Department of Health and Human Services that evaluates new pharmaceuticals, oversees postmarket safety, and issues regulatory guidance. It interacts with stakeholders including U.S. Congress, National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, and industry organizations like the Pharmaceutical Research and Manufacturers of America, while participating in international fora such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the Council for International Organizations of Medical Sciences.

History

Origins trace to regulatory reforms following high-profile events including the Sulfanilamide disaster of 1937 and the passage of the Federal Food, Drug, and Cosmetic Act; later statutory milestones such as the Kefauver Harris Amendment shaped its mission. Throughout the late 20th century the center evolved alongside initiatives from the Kennedy administration, Nixon administration, and policy shifts under the Food and Drug Amendments of 1962, Drug Price Competition and Patent Term Restoration Act of 1984, and the Food and Drug Administration Modernization Act of 1997. High-profile regulatory responses involved leadership engagement with events like the AIDS epidemic and the approval pathways established during the H1N1 influenza pandemic and crises addressed by coordination with the Assistant Secretary for Preparedness and Response.

Organization and Leadership

The center reports to the Commissioner of Food and Drugs and operates through directorates and offices that mirror structures in agencies such as the National Cancer Institute, Centers for Medicare & Medicaid Services, and the Office of Management and Budget for budgetary oversight. Leadership appointments have been influenced by confirmations in the United States Senate and interactions with the Office of Personnel Management and Government Accountability Office. Its internal organization includes divisions analogous to those in the European Medicines Agency and collaborates with review teams linked to the Office of the Inspector General (United States Department of Health and Human Services), while policy coordination involves the White House and the National Security Council on matters of emergency use.

Regulatory Responsibilities and Functions

The center enforces statutes such as the Federal Food, Drug, and Cosmetic Act and implements regulations codified in the Code of Federal Regulations. It regulates pharmaceuticals alongside other agencies like the Drug Enforcement Administration for controlled substances and interfaces with the Patent and Trademark Office on exclusivity matters and with the Federal Trade Commission on advertising. Regulatory functions include review of drug labeling consistent with precedents set in litigation before the Supreme Court of the United States and adjudicative interactions with the U.S. Court of Appeals for the Federal Circuit on approval disputes. The center participates in international regulatory convergence efforts with the European Commission, Health Canada, and the Pharmaceutical Inspection Co-operation Scheme.

Drug Approval Process

The review pathway encompasses stages comparable to those in New Drug Application frameworks and regulatory mechanisms used in Breakthrough Therapy designation and Orphan Drug Act incentives, requiring evidence from clinical trials overseen under standards similar to those promoted by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Applicants file dossiers resembling submissions to the European Medicines Agency and interact with advisory panels akin to those convened by the National Academies of Sciences, Engineering, and Medicine. The center evaluates chemistry, manufacturing, and controls data, clinical efficacy and safety evidence, and risk management plans consistent with precedents from high-profile approvals involving sponsors like Pfizer, Merck & Co., Johnson & Johnson, AstraZeneca, and GlaxoSmithKline.

Safety Surveillance and Pharmacovigilance

Postmarketing surveillance integrates reporting systems that parallel international systems such as those maintained by the World Health Organization and data-sharing initiatives with national bodies like the Public Health Agency of Canada and the European Centre for Disease Prevention and Control. The center conducts safety reviews, issues safety communications in coordination with the Centers for Disease Control and Prevention and the Office of the Surgeon General, and may require risk evaluation and mitigation strategies similar to actions taken during responses to safety signals identified for products from manufacturers including Bristol-Myers Squibb and Eli Lilly and Company. Enforcement actions can include recalls coordinated with the Consumer Product Safety Commission framework and legal remedies overseen in federal courts.

Research, Guidance, and Policy Development

The center produces guidance documents, scientific reports, and participates in regulatory science research in partnership with institutions such as the National Institutes of Health, Johns Hopkins University, Duke University, Harvard Medical School, and industry consortia including the Trans‑Celerate BioPharma. It contributes to policy development on topics addressed in forums like the World Health Assembly and collaborates with standards bodies such as the International Organization for Standardization. Academic collaborations, stakeholder workshops involving organizations like the American Medical Association, and public-private partnerships inform guidance on clinical trial design, biomarker qualification, and pediatric exclusivity established under statutes like the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.

Category:United States Food and Drug Administration